Cargando…

Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?

SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at cardiovascular risk http://ow.ly/p6Is300ffoc

Detalles Bibliográficos
Autores principales:	Andreas, Stefan, Janson, Christer, van den Berge, Maarten, Lahousse, Lies
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2016
Materias:	Clinical Signpost
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005175/ https://www.ncbi.nlm.nih.gov/pubmed/27730192 http://dx.doi.org/10.1183/23120541.00055-2016

Ejemplares similares

Diaphragm pacing and motor neurone disease: lessons for all?
por: Elliott, Mark W.
Publicado: (2015)

Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia
por: Torres, Antoni, et al.
Publicado: (2018)

Carbon footprint impact of the choice of inhalers for asthma and COPD
por: Janson, Christer, et al.
Publicado: (2020)

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
por: Janson, Christer, et al.
Publicado: (2017)

Reaching the summit of discharge summaries: a quality improvement project
por: Richmond, Richard Thomas, et al.
Publicado: (2021)

Impact of triple therapy on mortality in COPD
por: Soumagne, Thibaud, et al.
Publicado: (2023)

Tubercular Mortality: Have We Reached the Limit?
Publicado: (1914)

Have the “mega-journals” reached the limits to growth?
por: Björk, Bo-Christer
Publicado: (2015)

Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications
por: Agusti, Alvar, et al.
Publicado: (2021)

A pragmatic randomized controlled trial to improve inhaler technique using mHealth
por: Vanoverschelde, Anna, et al.
Publicado: (2020)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients
por: Ställberg, Björn, et al.
Publicado: (2020)

Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas
por: Giotta Lucifero, Alice, et al.
Publicado: (2020)

Revisiting IL-13 blockade: can we reach the wonderland the inhaled way?
por: Papaioannou, Andriana I., et al.
Publicado: (2018)

Determinants of poor inhaler technique and poor therapy adherence in obstructive lung diseases: a cross-sectional study in community pharmacies
por: Vanoverschelde, Anna, et al.
Publicado: (2021)

Decoding methods for neural prostheses: where have we reached?
por: Li, Zheng
Publicado: (2014)

Sleep breathing disorders: have we reached the tipping point?
por: Suarez-Giron, Monique C., et al.
Publicado: (2018)

Rhythm Control in AF: Have We Reached the Last Frontier?
por: Dan, Gheorghe-Andrei
Publicado: (2019)

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
por: Brigham, Emily P., et al.
Publicado: (2021)

Patients with underuse or overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhaled medication
por: Koehorst-ter Huurne, Kirsten, et al.
Publicado: (2018)

Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations
por: Sulku, Johanna, et al.
Publicado: (2021)

Methods to assess COPD medications adherence in healthcare databases: a systematic review
por: Vauterin, Delphine, et al.
Publicado: (2023)

Fast-track hip and knee arthroplasty – have we reached the goal?
por: Wainwright, Thomas W, et al.
Publicado: (2019)

Diabetic Pregnancy 1977–1990: Have We Reached a Plateau?
por: Gregory, R., et al.
Publicado: (1992)

Prevention of the first episode of psychosis: What have we reached by 2021?
por: Rojnic-Kuzman, M.
Publicado: (2021)

Rodent models of postherpetic neuralgia: How far have we reached?
por: Ou, Mingxi, et al.
Publicado: (2023)

Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study
por: Terzikhan, Natalie, et al.
Publicado: (2016)

What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape
por: Lavorini, Federico, et al.
Publicado: (2019)

A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden
por: Sulku, Johanna, et al.
Publicado: (2019)

The ‘Lost’ frontier of clinical medicine: Have we reached a point of no return?
por: Dalvi, Bharat
Publicado: (2009)

Coronary Heart Disease: Have We Reached a Plateau in Primary Prevention?
por: Case, Brian C., et al.
Publicado: (2020)

National Mental Health Policy, India (2014): Where Have We Reached?
por: Gupta, Snehil, et al.
Publicado: (2021)

Liver Regeneration by Hematopoietic Stem Cells: Have We Reached the End of the Road?
por: Siapati, Elena Konstantina, et al.
Publicado: (2022)

Amazing pleiotropic effects of azithromycin
por: Lahousse, Lies
Publicado: (2018)

Epigenetic targets for lung diseases
por: Lahousse, Lies
Publicado: (2019)

Prevalence of Asthma and COPD and Blood Eosinophil Count in a Middle-Aged Belgian Population
por: Wijnant, Sara R. A., et al.
Publicado: (2019)

Khoisan hunter-gatherers have been the largest population throughout most of modern-human demographic history
por: Kim, Hie Lim, et al.
Publicado: (2014)

Current developments and future directions in COPD
por: Mathioudakis, Alexander G., et al.
Publicado: (2020)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
por: Celli, Bartolome R, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nithqhe9efvqmek8m5qa0bgfn3